CD44 and cancer: The flow cytometry analysisof ASCs revealed that more than 90% of all cancer andnormal ASCs were positive for the stem cell specificmarkers, including CD90, CD105, CD44 and CD73, butthey were negative for the expression of hematopoieticspecific markers, such as CD45, CD34 and CD14 (Fig .1B).